Monte Rosa Therapeutics, Inc. Capital Expenditures Incurred but Not yet Paid
Monte Rosa Therapeutics, Inc. (GLUE) reported Capital Expenditures Incurred but Not yet Paid of $1.45 million for the 6-month period ending 2026-06-30, per its 10-Q filed 2026-08-06.
Financial Statements › Cash Flow › Other Cash Flow Items
us-gaap:CapitalExpendituresIncurredButNotYetPaid · last filed 2026-08-06
- Monte Rosa Therapeutics, Inc. capital expenditures incurred but not yet paid for the quarter ending 2026-06-30 was -$1.29M, a 980.82% decline year-over-year.
- Monte Rosa Therapeutics, Inc. capital expenditures incurred but not yet paid for the quarter ending 2026-03-31 was $2.74M, a 800.00% increase year-over-year.
- Monte Rosa Therapeutics, Inc. capital expenditures incurred but not yet paid for the quarter ending 2025-12-31 was -$290.00K.
- Monte Rosa Therapeutics, Inc. capital expenditures incurred but not yet paid for the quarter ending 2025-09-30 was -$11.00K.
- Monte Rosa Therapeutics, Inc. capital expenditures incurred but not yet paid for fiscal 2025 was $149.00K, a 198.00% increase from fiscal 2024.
- Monte Rosa Therapeutics, Inc. capital expenditures incurred but not yet paid for fiscal 2024 was $50.00K, a 78.90% decline from fiscal 2023.
- Monte Rosa Therapeutics, Inc. capital expenditures incurred but not yet paid for fiscal 2023 was $237.00K, a 96.20% decline from fiscal 2022.
- Monte Rosa Therapeutics, Inc. capital expenditures incurred but not yet paid for fiscal 2022 was $6.24M, a 851.22% increase from fiscal 2021.
| Period end | Capital Expenditures Incurred but Not yet Paid 3 month | Capital Expenditures Incurred but Not yet Paid 6 month | Capital Expenditures Incurred but Not yet Paid 9 month | Capital Expenditures Incurred but Not yet Paid 12 month |
|---|---|---|---|---|
| 2026-06-30 | -$1.29M derived: 10-Q 6 month − 10-Q 3 month · filed 2026-08-06 | $1.45M 10-Q · filed 2026-08-06 | $1.16M derived: sum of 3 quarters · filed 2026-08-06 | $1.15M derived: sum of 4 quarters · filed 2026-08-06 |
| 2026-03-31 | $2.74M 10-Q · filed 2026-05-07 | $2.45M derived: sum of 2 quarters · filed 2026-05-07 | $2.44M derived: sum of 3 quarters · filed 2026-05-07 | $2.58M derived: sum of 4 quarters · filed 2026-08-06 |
| 2025-12-31 | -$290.00K derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-17 | -$301.00K derived: sum of 2 quarters · filed 2026-03-17 | -$155.00K derived: sum of 3 quarters · filed 2026-08-06 | $149.00K 10-K · filed 2026-03-17 |
| 2025-09-30 | -$11.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-06 | $135.00K derived: sum of 2 quarters · filed 2026-08-06 | $439.00K 10-Q · filed 2025-11-06 | $358.00K derived: sum of 4 quarters · filed 2026-08-06 |
| 2025-06-30 | $146.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2026-08-06 | $450.00K 10-Q · filed 2026-08-06 | $369.00K derived: sum of 3 quarters · filed 2026-08-06 | $265.00K derived: sum of 4 quarters · filed 2026-08-06 |
| 2025-03-31 | $304.00K 10-Q · filed 2026-05-07 | $223.00K derived: sum of 2 quarters · filed 2026-05-07 | $119.00K derived: sum of 3 quarters · filed 2026-05-07 | -$629.00K derived: sum of 4 quarters · filed 2026-05-07 |
| 2024-12-31 | -$81.00K derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-17 | -$185.00K derived: sum of 2 quarters · filed 2026-03-17 | -$933.00K derived: sum of 3 quarters · filed 2026-03-17 | $50.00K 10-K · filed 2026-03-17 |
| 2024-09-30 | -$104.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-06 | -$852.00K derived: sum of 2 quarters · filed 2025-11-06 | $131.00K 10-Q · filed 2025-11-06 | -$902.00K derived: sum of 4 quarters · filed 2025-11-06 |
| 2024-06-30 | -$748.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2025-08-07 | $235.00K 10-Q · filed 2025-08-07 | -$798.00K derived: sum of 3 quarters · filed 2025-08-07 | -$966.00K derived: sum of 4 quarters · filed 2025-08-07 |
| 2024-03-31 | $983.00K 10-Q · filed 2025-05-08 | -$50.00K derived: sum of 2 quarters · filed 2025-05-08 | -$218.00K derived: sum of 3 quarters · filed 2025-05-08 | -$3.18M derived: sum of 4 quarters · filed 2025-05-08 |
| 2023-12-31 | -$1.03M derived: 10-K 12 month − 10-Q 9 month · filed 2025-03-20 | -$1.20M derived: sum of 2 quarters · filed 2025-03-20 | -$4.17M derived: sum of 3 quarters · filed 2025-03-20 | $237.00K 10-K · filed 2025-03-20 |
| 2023-09-30 | -$168.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2024-11-07 | -$3.13M derived: sum of 2 quarters · filed 2024-11-07 | $1.27M 10-Q · filed 2024-11-07 | $2.76M derived: sum of 4 quarters · filed 2024-11-07 |
| 2023-06-30 | -$2.96M derived: 10-Q 6 month − 10-Q 3 month · filed 2024-08-08 | $1.44M 10-Q · filed 2024-08-08 | $2.93M derived: sum of 3 quarters · filed 2024-08-08 | $6.74M derived: sum of 4 quarters · filed 2024-08-08 |
| 2023-03-31 | $4.40M 10-Q · filed 2024-05-09 | $5.89M derived: sum of 2 quarters · filed 2024-05-09 | $9.70M derived: sum of 3 quarters · filed 2024-05-09 | $9.85M derived: sum of 4 quarters · filed 2024-05-09 |
| 2022-12-31 | $1.49M derived: 10-K 12 month − 10-Q 9 month · filed 2024-03-14 | $5.30M derived: sum of 2 quarters · filed 2024-03-14 | $5.45M derived: sum of 3 quarters · filed 2024-03-14 | $6.24M 10-K · filed 2024-03-14 |
| 2022-09-30 | $3.81M derived: 10-Q 9 month − 10-Q 6 month · filed 2023-11-09 | $3.96M derived: sum of 2 quarters · filed 2023-11-09 | $4.75M 10-Q · filed 2023-11-09 | $3.50M derived: sum of 4 quarters · filed 2023-11-09 |
| 2022-06-30 | $145.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2023-08-10 | $939.00K 10-Q · filed 2023-08-10 | -$314.00K derived: sum of 3 quarters · filed 2023-08-10 | $1.47M derived: sum of 4 quarters · filed 2023-08-10 |
| 2022-03-31 | $794.00K 10-Q · filed 2023-05-11 | -$459.00K derived: sum of 2 quarters · filed 2023-05-11 | $1.33M derived: sum of 3 quarters · filed 2023-05-11 | $284.00K derived: sum of 4 quarters · filed 2023-05-11 |
| 2021-12-31 | -$1.25M derived: 10-K 12 month − 10-Q 9 month · filed 2023-03-16 | $533.00K derived: sum of 2 quarters · filed 2023-03-16 | -$510.00K derived: sum of 3 quarters · filed 2023-03-16 | $656.00K 10-K · filed 2023-03-16 |
| 2021-09-30 | $1.79M derived: 10-Q 9 month − 10-Q 6 month · filed 2022-11-10 | $743.00K derived: sum of 2 quarters · filed 2022-11-10 | $1.91M 10-Q · filed 2022-11-10 | $1.89M derived: sum of 4 quarters · filed 2022-11-10 |
| 2021-06-30 | -$1.04M derived: 10-Q 6 month − 10-Q 3 month · filed 2022-08-11 | $123.00K 10-Q · filed 2022-08-11 | $103.00K derived: sum of 3 quarters · filed 2022-08-11 | $249.00K derived: sum of 4 quarters · filed 2022-08-11 |
| 2021-03-31 | $1.17M 10-Q · filed 2022-05-11 | $1.15M derived: sum of 2 quarters · filed 2022-05-11 | $1.29M derived: sum of 3 quarters · filed 2022-05-11 | |
| 2020-12-31 | -$20.00K derived: 10-K 12 month − 10-Q 9 month · filed 2022-03-29 | $126.00K derived: sum of 2 quarters · filed 2022-03-29 | $458.00K 10-K · filed 2022-03-29 | |
| 2020-09-30 | $146.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2021-11-10 | $478.00K 10-Q · filed 2021-11-10 | ||
| 2020-06-30 | $332.00K 10-Q · filed 2021-08-12 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Cullinan Therapeutics, Inc. (CGEM) | United States | $0.993B | -5.72 |
| Odyssey Therapeutics, Inc. (ODTX) | United States | $0.960B | |
| MeiraGTx Holdings plc (MGTX) | United States | $1.061B | 16.10 |
| Vor Biopharma Inc. (VOR) | United States | $1.091B | 1.60 |
| Sana Biotechnology, Inc. (SANA) | United States | $0.886B | -4.92 |
| Candel Therapeutics, Inc. (CADL) | United States | $0.885B | -8.86 |
| Attovia Therapeutics, Inc. (ATTO) | United States | $0.828B | |
| Replimune Group, Inc. (REPL) | United States | $1.186B | -3.13 |
| Solid Biosciences Inc. (SLDB) | United States | $0.802B | -5.07 |
| 4D Molecular Therapeutics, Inc. (FDMT) | United States | $0.733B | -4.10 |